Literature DB >> 8956458

Do human cancers express shared protective antigens? or the necessity of remembrance of things past.

P K Srivastava1.   

Abstract

A majority of CTL-recognized antigens of human melanomas have turned out to be unmutated differentiation antigens expressed on melanomas and melanocytes alike. Additional, relatively cancer-specific antigens which are expressed on a significant proportion of melanomas, but not on most normal tissues, have also been shown to be recognized by CTLs. Finally, CTLs have been shown to detect mutated oncoproteins which are expressed in a wide spectrum of cancers but not in normal tissues. These observations have given rise to a view that human cancers share a number of antigens, which can form the basis for their immunotherapy. In contrast, cancer antigens of mice and rats (which are detected by tumor rejection assays in vivo, rather than CTLs generated in vitro) have been observed, generally, to be individually distinct, i.e. unique for each individual cancer. No convincing examples of shared cancer antigens exist in animal models of cancer. This dichotomy between the nature of cancer antigens of humans ('shared'), and of rodents ('unique') is addressed, and hopefully, resolved in this article.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8956458     DOI: 10.1006/smim.1996.0038

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  11 in total

Review 1.  Heat shock proteins: the fountainhead of innate and adaptive immune responses.

Authors:  S Basu; P K Srivastava
Journal:  Cell Stress Chaperones       Date:  2000-11       Impact factor: 3.667

Review 2.  "It is the antigen(s), stupid" and other lessons from over a decade of vaccitherapy of human cancer.

Authors:  Matthew R Buckwalter; Pramod K Srivastava
Journal:  Semin Immunol       Date:  2008-08-20       Impact factor: 11.130

Review 3.  The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice.

Authors:  I M Svane; M Boesen; A M Engel
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

4.  Identification of chaperones as essential components of the tumor rejection moieties of cancers.

Authors:  Pramod K Srivastava
Journal:  Cancer Immun       Date:  2012-05-01

5.  Immunosurveillance of cancer and the heat shock protein-CD91 pathway.

Authors:  Robert J Binder
Journal:  Cell Immunol       Date:  2018-05-16       Impact factor: 4.868

6.  HSP70 peptidembearing and peptide-negative preparations act as chaperokines.

Authors:  A Asea; E Kabingu; M A Stevenson; S K Calderwood
Journal:  Cell Stress Chaperones       Date:  2000-11       Impact factor: 3.667

7.  A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma.

Authors:  G W Wood; F P Holladay; T Turner; Y Y Wang; M Chiga
Journal:  J Neurooncol       Date:  2000-06       Impact factor: 4.130

8.  Modeling the repertoire of true tumor-specific MHC I epitopes in a human tumor.

Authors:  Nisheeth Srivastava; Pramod K Srivastava
Journal:  PLoS One       Date:  2009-07-10       Impact factor: 3.240

Review 9.  Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges.

Authors:  Pramod K Srivastava; Fei Duan
Journal:  Cancer Immunol Immunother       Date:  2013-04-19       Impact factor: 6.968

10.  Heat shock proteins: conditional mediators of inflammation in tumor immunity.

Authors:  Stuart K Calderwood; Ayesha Murshid; Jianlin Gong
Journal:  Front Immunol       Date:  2012-04-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.